GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rennova Health Inc (OTCPK:RNVA) » Definitions » ROE %

Rennova Health (Rennova Health) ROE % : 0.00% (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Rennova Health ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Rennova Health's annualized net income for the quarter that ended in Sep. 2023 was $-2.19 Mil. Rennova Health's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-27.29 Mil. Therefore, Rennova Health's annualized ROE % for the quarter that ended in Sep. 2023 was N/A%.

The historical rank and industry rank for Rennova Health's ROE % or its related term are showing as below:

RNVA' s ROE % Range Over the Past 10 Years
Min: -95.09   Med: -66.9   Max: Negative Equity
Current: Negative Equity

During the past 13 years, Rennova Health's highest ROE % was Negative Equity%. The lowest was -95.09%. And the median was -66.90%.

RNVA's ROE % is ranked better than
99.54% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.58 vs RNVA: Negative Equity

Rennova Health ROE % Historical Data

The historical data trend for Rennova Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rennova Health ROE % Chart

Rennova Health Annual Data
Trend Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - Negative Equity -

Rennova Health Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Equity Negative Equity Negative Equity -

Competitive Comparison of Rennova Health's ROE %

For the Diagnostics & Research subindustry, Rennova Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rennova Health's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rennova Health's ROE % distribution charts can be found below:

* The bar in red indicates where Rennova Health's ROE % falls into.



Rennova Health ROE % Calculation

Rennova Health's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-3.293/( (-27.302+-29.095)/ 2 )
=-3.293/-28.1985
=N/A %

Rennova Health's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-2.192/( (-27.011+-27.559)/ 2 )
=-2.192/-27.285
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Rennova Health  (OTCPK:RNVA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-2.192/-27.285
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.192 / 14.152)*(14.152 / 20.7)*(20.7 / -27.285)
=Net Margin %*Asset Turnover*Equity Multiplier
=-15.49 %*0.6837*N/A
=ROA %*Equity Multiplier
=-10.59 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-2.192/-27.285
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.192 / -2.96) * (-2.96 / -2.404) * (-2.404 / 14.152) * (14.152 / 20.7) * (20.7 / -27.285)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7405 * 1.2313 * -16.99 % * 0.6837 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Rennova Health ROE % Related Terms

Thank you for viewing the detailed overview of Rennova Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rennova Health (Rennova Health) Business Description

Traded in Other Exchanges
N/A
Address
400 S. Australian Avenue, Suite 800, West Palm Beach, FL, USA, 33401
Rennova Health Inc is a vertically integrated provider of healthcare-related products and services. The company operates through a single business segment namely the Hospital operations segment reflects the purchase of the hospital assets. Geographically, the activities are carried out throughout the region of the US.
Executives
Jonathan Immordino officer: Chief Financial Officer 3340, POSEIDON WAY, INDIALANTIC FL 32903
Marlene Mclennan officer: Chief Financial Officer 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Gary L Blum director 3278 WILSHIRE BOULEVARD, SUITE 603, LOS ANGELES, CALIFORNIA CA 90010
John Beach director 400 S. AUSTRALIAN AVENUE,, SUITE 800,, WEST PALM BEACH, FL 33401
Kamran Ajami director 3920 NW 43RD ST., COCONUT CREEK FL 33073
Trevor Langley director 1000 N. GREEN VALLEY PARKWAY, #440-420, HENDERSON NV 89074
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Sharon Lynne Hollis 10 percent owner 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Robert P Lee director 400 S. AUSTRALIAN AVE., #800, WEST PALM BEACH FL 33134
Aella, Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Epizon Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Michael Louis Goldberg director 2008 BAYVIEW DRIVE, FORT LAUDERDALE FL 33305
Benjamin Frank director 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Jason Adams officer: Chief Financial Officer 4700 SANTA DEL RAE AVENUE, FT MYERS FL 33901
George Lundberg officer: Editor in Chief and CMO 44 MONTGOMERY STREET, SUITE 800, SAN FRANCISCO CA 94104

Rennova Health (Rennova Health) Headlines